Progression of mild untreated heart failure during six months follow-up and clinical and neurohumoral effects of ibopamine and digoxin as monotherapy. DIMT Study Group. Dutch Ibopamine Multicenter Trial.
There is increasing evidence that clinical deterioration in manifest chronic heart failure is related to both hemodynamic and neurohumoral factors. Only few data are available, however, on the progression of disease in its early stages, when treatment has not yet been initiated. The aim of this study was therefore to examine the changes in clinical and neurohumoral variables that occur over 6 months in patients with clinically stable and untreated heart failure, and to evaluate the influence of drugs that may affect these variables. Accordingly, we studied 64 patients with heart failure who were in New York Heart Association functional class II (88%) and III (12%). They were randomized to double-blind treatment with the oral dopamine agonist ibopamine (100 mg 3 times daily; n = 22), digoxin (0.25 mg once daily; n = 22) or placebo (n = 20). Their age (mean +/- SD) was 60 +/- 8 years, and left ventricular ejection fraction (mean +/- SD) was 0.33 +/- 0.08. Of the 64 patients, 56 (88%) completed the 6-month study period (p = NS between groups). Exercise time decreased in patients treated with placebo after 6 months (median -62 seconds; p < 0.05 vs baseline), but it increased with ibopamine (+48 seconds), and digoxin (+17 seconds; both p < 0.05 vs placebo). Plasma norepinephrine increased in the placebo group after 6 months (median + 31 pg/ml, p < 0.05 vs baseline), but decreased in patients receiving active drug treatment (ibopamine: -24 pg/ml, digoxin: -98 pg/ml, both p < 0.05 vs placebo). Plasma renin and aldosterone levels were unchanged after 6 months in the placebo group, but digoxin therapy slightly reduced plasma renin concentration (-5 microU/ml; p < 0.05 vs placebo).(ABSTRACT TRUNCATED AT 250 WORDS)
van Veldhuisen
D J
DJ
Department of Cardiology/Thoraxcenter, University Hospital Groningen, The Netherlands.
Brouwer
J
J
Man in 't Veld
A J
AJ
Dunselman
P H
PH
Boomsma
F
F
Lie
K I
KI
D000293:Adolescent; D000328:Adult; D000368:Aged; D002303:Cardiac Output, Low / Q000188:drug therapy* / Q000503:physiopathology*; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003846:Deoxyepinephrine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004077:Digoxin / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D018377:Neurotransmitter Agents / Q000502:physiology*; D009638:Norepinephrine / Q000097:blood; D005082:Physical Exertion / Q000502:physiology; D010919:Placebos; D012083:Renin / Q000097:blood; D013318:Stroke Volume / Q000502:physiology; D016277:Ventricular Function, Left / Q000502:physiology
D002316:Cardiotonic Agents; D018491:Dopamine Agonists; D018377:Neurotransmitter Agents; D010919:Placebos; D004077:Digoxin; C023487:ibopamine; D012083:Renin; D003846:Deoxyepinephrine; D009638:Norepinephrine